Abstract
This study aimed to assess the risk factors of the hand-foot skin reaction (HFSR) caused by sorafenib in patients with advanced hepatocellular carcinoma, and to elucidate the significant factors on management of HFSR. The study subjects were patients with hepatocellular carcinoma treated by sorafenib from June 2009 to Sep 2010. There were 60 male and seven female patients. The Eastern Cooperative Oncology Group performance status (PS) was 0, 1 and 2 in 54, 21 and 1 patients, respectively. Among 67 patients, all grades of HFSR were observed in 50 patients (74.6％), and the maximum grade of HFSR was 0, 1, 2 and 3 in 17 (25.4％), 12 (17.9％), 35 (52.2％) and 3 patients (4.5％), respectively. In the patients characteristics prior to the administration of sorafenib, the incidence of grade 2 or 3 of HFSR was significantly higher in patients with PS 0 than those with PS 1 or 2. And in the daily life factor, the incidence of grade 2 or 3 of HFSR was significantly higher in patients who have risk of “when grasping an item, working or cooking in which pressure is exerted, the occurrence of stimulation by friction and detergent, etc.” than those without these factors. In the multivariate analysis, PS 0 was an independent significant risk factor of HFSR caused by sorafenib. In conclusion, the strict management of HFSR was warranted in patients with good PS, because the incidence of grade 2 or more of HFSR was significantly higher in patients with good PS.
